- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Home > Press > Shape of nanoparticles points the way toward more targeted drugs: A collaboration of scientists at Sanford-Burnham and the University of California, Santa Barbara, finds that rod-shaped particles, rather than spherical particles, appear more effective at adhering to cells
|Sanford-Burnham's Erkki Ruoslahti, M.D., Ph.D., is a co-author of the study.|
Conventional treatments for diseases such as cancer can carry harmful side effects—and the primary reason is that such treatments are not targeted specifically to the cells of the body where they're needed. What if drugs for cancer, cardiovascular disease, and other diseases can be targeted specifically and only to cells that need the medicine, and leave normal tissues untouched?
A new study involving Sanford-Burnham Medical Research Institute's Erkki Ruoslahti, M.D., Ph.D., contributing to work by Samir Mitragotri, Ph.D., at the University of California, Santa Barbara, found that the shape of nanoparticles can enhance drug targeting. The study, published in Proceedings of the National Academy of Sciences, found that rod-shaped nanoparticles—or nanorods—as opposed to spherical nanoparticles, appear to adhere more effectively to the surface of endothelial cells that line the inside of blood vessels.
"While nanoparticle shape has been shown to impact cellular uptake, the latest study shows that specific tissues can be targeted by controlling the shape of nanoparticles. Keeping the material, volume, and the targeting antibody the same, a simple change in the shape of the nanoparticle enhances its ability to target specific tissues," said Mitragotri.
"The elongated particles are more effective," added Ruoslahti. "Presumably the reason is that if you have a spherical particle and it has binding sites on it, the curvature of the sphere allows only so many of those binding sites to interact with membrane receptors on the surface of a cell."
In contrast, the elongated nanorods have a larger surface area that is in contact with the surface of the endothelial cells. More of the antibodies that coat the nanorod can therefore bind receptors on the surface of endothelial cells, and that leads to more effective cell adhesion and more effective drug delivery.
Testing targeted nanoparticles
Mitragotri's lab tested the efficacy of rod-shaped nanoparticles in synthesized networks of channels called "synthetic microvascular networks," or SMNs, that mimic conditions inside blood vessels. The nanoparticles were also tested in vivo in animal models, and separately in mathematical models.
The researchers also found that nanorods targeted to lung tissue in mice accumulated at a rate that was two-fold over nanospheres engineered with the same targeting antibody. Also, enhanced targeting of nanorods was seen in endothelial cells in the brain, which has historically been a challenging organ to target with drugs.
Nanoparticles already used in some cancer drugs
Nanoparticles have been studied as vessels to carry drugs through the body. Once they are engineered with antibodies that bind to specific receptors on the surface of targeted cells, these nanoparticles also can, in principle, become highly specific to the disease they are designed to treat.
Ruoslahti, a pioneer in the field of cell adhesion—how cells bind to their surroundings—has developed small chain molecules called peptides that can be used to target drugs to tumors and atherosclerotic plaques.
"Greater specific attachment exhibited by rod-shaped particles offers several advantages in the field of drug delivery, particularly in the delivery of drugs such as chemotherapeutics, which are highly toxic and necessitate the use of targeted approaches," the authors wrote in their paper.
The studies demonstrate that nanorods with a high aspect ratio attach more effectively to targeted cells compared with spherical nanoparticles. The findings hold promise for the development of novel targeted therapies with fewer harmful side effects.
We acknowledge support from a California Institute of Regenerative Medicine Fellowship, a National Science Foundation (NSF) Graduate Research Fellowship under Grant DGE-1144085, and the Materials Research Science and Engineering Centers Program of the NSF under Award Division of Materials Research 1121053.
The study was co-authored by Poornima Kolhar, UC Santa Barbara; Aaron C. Anselmo, UC Santa Barbara; Vivek Gupta, UC Santa Barbara; Kapil Pant, UC Santa Barbara; Balabhaskar Prabhakarpandian, UC Santa Barbara; Erkki Ruoslahti, Sanford-Burnham and UC Santa Barbara; and Samir Mitragotri, UC Santa Barbara.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200 scientists and staff in San Diego (La Jolla), California, and Orlando (Lake Nona), Florida. For more information, visit us at sanfordburnham.org.
For more information, please click here
Copyright © Sanford-Burnham Medical Research InstituteIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Argon is not the 'dope' for metallic hydrogen March 24th, 2017
“Cysteine Rose” Wins 2016 Thermo Fisher Scientific Electron Microscopy Image Contest: Thermo Fisher honors Andrea Jacassi of the Italian Institute of Technology for image of cysteine crystals using focused ion beam techniques March 27th, 2017
Argon is not the 'dope' for metallic hydrogen March 24th, 2017
ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017
Leti and HORIBA Scientific to Host Webinar on Ultrafast Characterization Tool: Plasma Profiling Time-of-Flight Mass Spectrometer Tool Cuts Optimization Time In Layer Deposition and Fabrication of Wide Range of Applications March 27th, 2017